• Sign In
  • FAQ
  • Create an Account
Currency
USD currency flagUSD
Toggle Nav
My Cart
Menu
Account
Settings
Currency
USD currency flagUSD

Cell Cycle

Items 51-100 of 1565

Page
per page
Set Descending Direction
Catalog No.
Product Name
Application
Product Information
Citations
  1. A11001
    Y-27632 2HCl

    ROCK Inhibitor

    Y-27632 is a Rho-Associated Coil Kinase (ROCK) inhibitor that increases the cloning efficiency of human embryonic stem cells (hESCs).
    Quick View
  2. A12912
    CASIN

    Cdc42 GTPase inhibitor

    CASIN is a novel and potent Cdc42 inhibitor.
    Quick View
  3. A14427
    Palbociclib

    CDK inhibitor

    Palbociclib is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity.
    Quick View
  4. A10494
    JNJ-7706621

    CDK/Aurora A/B Inhibitor

    JNJ-7706621 is pan-CDK inhibitor with the highest potency on CDK1/2 with IC50 of 9 nM/4 nM and showing >6-fold selectivity for CDK1/2 than CDK3/4/6 in cell-free assays. It also potently inhibits Aurora A/B and has no activity on Plk1 and Wee1.
    Quick View
  5. A12352
    Purvalanol B

    CDK inhibitor

    Purvalanol B is a cyclin-dependent kinase inhibitor. IC50 values are 6, 6, 9, > 10,000, and 6 nM for cdc2/cyclin B, cdk2/cyclin A, cdk2/cyclin E, cdk4/cyclin D1 and cdk5-p35 respectively. Selective over a range of other protein kinases (IC50 > 10,000 nM).
    Quick View
  6. A12407
    TMPA

    Nur77 LBD Antagonist

    TMPA is a novel small molecule that binds to orphan Nuclear Receptor Nur77 with high affinity (Kd = 1.45 ?? 0.35 μM), and interferes with the Nur77-LKB1 interaction.
    Quick View
  7. A12438
    NU 6102

    CDK inhibitor

    NU6102 is selective for CDK1 and CDK2 compared to CDK4/D1 (IC50=1.6 μM), DYRK1A (IC50=0.9 μM), PDK1 (IC50=0.8 μM) and ROCKII (IC50=0.6 μM).
    Quick View
  8. A12464
    AT13148

    multi-AGC kinase inhibitor

    AT13148 is a novel oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity, which shows a distinct mechanism of action from other AKT inhibitors.
    Quick View
  9. A12494
    NG52

    Cell cycle-regulating kinase inhibitor

    NG52 is a potent, cell-permeable, reversible, selective, and ATP-compatible inhibitor of the cell cycle-regulating kinase, Cdc28p (IC50 = 7 _mu_M), and the related Pho85p kinase (IC50 = 2 _mu_M).
    Quick View
  10. A12513
    Cdc7-IN-1

    Cdc7 kinase inhibitor

    Cdc7-IN-1 (Compound 13) is a highly potent, selective and ATP competitive inhibitor of Cdc7 kinase, with an IC50 value of 0.6 nM at 1 mM ATP and with slow off-rate characteristics.
    Quick View
  11. A12542
    ARS-853

    KRAS G12C inhibitor

    ARS-853 is a cell-active, selective, covalent KRAS G12C inhibitor with an IC50 of 2.5 μM. ARS-853 inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein and preventing activation.
    Quick View
  12. A12546
    NSC 23766

    Rac1 activation inhibitor

    NSC 23766 is a selective inhibitor of Rac1-GEF interaction. Prevents Rac1 activation by Rac-specific guanine nucleotide exchange factors (GEFs) TrioN and Tiam1 (IC50 ~ 50 μM) without affecting Cdc42 or RhoA activation.
    Quick View
  13. A12578
    Kobe2602

    Ras?€?Raf inhibitor

    Kobe2602 is an analog of Kobe0065. Exhibits potent activity to competitively inhibit the binding of H-Ras??GTP to c-Raf-1 RBD with a Ki value of 149 ?? 55 μM.
    Quick View
  14. A12584
    ON123300

    CDK4 inhibitor?€?

    ON123300 is a potent multikinase inhibitor and may be potential useful for brain tumor chemotherapy. ON123300 strongly inhibits Ark5 and CDK4, as well as growth factor receptor tyrosine kinases such as ??-type platelet-derived growth factor receptor (PDGFR??).
    Quick View
  15. A12586
    EHT 1610

    DYRK inhibitor

    EHT 1610 is a highly potent and selective inhibitor of dual-specificity tyrosine-phosphorylation-regulated kinases (DYRK), exhibiting IC₅₀ values of 0.36 nM for DYRK1A and 0.59 nM for DYRK1B. EHT 1610 demonstrates significant antileukemic activity, associated with modulation of cell cycle progression and induction of apoptotic pathways in target cells.

    Quick View
  16. A12644
    MSC2530818

    CDK8 inhibitor

    MSC2530818 is a potent, selective and orally available CDK8 inhibitor with an IC50 of 2.6 nM for CDK8.
    Quick View
  17. A12674
    SR 3677

    ROCK inhibitor

    SR 3677  is a potent and selective Rho-kinase inhibitor (IC50 values are 3 and 56 nM for ROCK-II and ROCK-I respectively).

    Quick View
  18. A12703
    SCH900776 (S-isomer)

    CHK1 Inhibitor

    SCH900776 is an agent targeting cell cycle checkpoint kinase 1 (Chk1) with potential radiosensitization and chemosensitization activities.
    Quick View
  19. A12717
    Pyridostatin
    Pyridostatin is a G-quadruplex-interacting drug which can promote growth arrest in human cancer cells by inducing replication- and transcription-dependent DNA damage.
    Quick View
  20. A12740
    EHop-016

    Rac GTPase Inhibitor

    EHop-016 is a potent and specific inhibitor of Rac1 and Rac3 GTPase activity that inhibits Vav2 interaction with Rac, Rac-activated PAK1, lamellipodia formation, and cell migration.
    Quick View
  21. A12839
    BMS-5

    LIMK inhibitor

    BMS-5 is a potent LIMK inhibitor with IC50s of 7 nM and 8 nM for LIMK1 and LIMK2, respectively.
    Quick View
  22. A12922
    ID 8

    DYRK inhibitor

    ID-8 is a DYRK inhibitor. ID 8 also stimulates proliferation at a steady rate (observed in serum-free media supplemented with 10 μM over a 30 day period).
    Quick View
  23. A12961
    CDK8-IN-1

    CDK8 inhibitor

    CDK8-IN-1 is a potent and selective CDK8 inhibitor with an IC50 of 3 nM.
    Quick View
  24. A12972
    KRas G12C inhibitor 4

    KRas G12C inhibitor

    KRas G12C inhibitor 1 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.
    Quick View
  25. A13018
    KRas G12C inhibitor 3

    Kras-G12C inhibitor

    KRas G12C inhibitor 3 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.
    Quick View
  26. A13045
    NMS-1286937

    PLK inhibitor

    NMS-1286937 is an orally bioavailable, small-molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity.
    Quick View
  27. A13064
    KRas G12C inhibitor 2

    Kras-G12C inhibitor

    KRas G12C inhibitor 2 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.
    Quick View
  28. A13067
    RKI-1447

    ROCK1/ROCK2 inhibitor

    RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer.
    Quick View
  29. A13069
    XL-228

    IGF-1R, Aurora, FGFR, ABL, SRC inhibitor

    XL228 is a protein kinase inhibitor targeting IGF1R, the AURORA kinases, FGFR1-3, ABL and SRC family kinases. XL228 is an Aurora A inhibitor (IC50, f3 nmol/L) that has shown potent biochemical activity against ABL1 (Ki, 5 nmol/L), as well as the BCR-ABL1 T315I (Ki, 1.4 nmol/L) kinases.
    Quick View
  30. A13112
    GGTI-2418

    GGTase inhibitor

    GGTI-2418 is a synthetic peptidomimetic inhibitor of geranylgeranyltransferase I (GGTase I) that appears to induce apoptosis by downregulating several pivotal oncogenic and tumor survival pathways.
    Quick View
  31. A13119
    Balamapimod (MKI-833)

    Ras/Raf/MEK inhibitor

    Balamapimod, also known as MKI-822, is a Ras/Raf/MEK inhibitor.
    Quick View
  32. A13130
    RGB-286638

    CDK inhibitor

    RGB-286638 is a novel CDK inhibitor with IC50s of 1 nM/2 nM/3 nM/4 nM/5 nM for cyclin T1-CDK9/cyclin B1-CDK1/cyclin E-CDK2/cyclin D1-CDK4/cyclin E-CDK3/p35-CDK5 respectively; less potent against cyclin H-CDK7 and cyclin D3-CDK6.
    Quick View
  33. A13135
    Kobe0065

    Ras-Raf interaction inhibitor

    Kobe0065 inhibits anchorage-dependent and -independent growth, blocks MEK/ERK activity and induces apoptosis in H-rasG12V transformed NIH3T3 cells.
    Quick View
  34. A13142
    CHK1-IN-2

    CHK1 inhibitor

    CHK1-IN-2 is a checkpoint kinase 1 (CHK1) inhibitor, with an IC50 of 6 nM.
    Quick View
  35. A13152
    KRas G12C inhibitor 1

    Kras-G12C inhibitor 1

    KRas G12C inhibitor 1 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.
    Quick View
  36. A13160
    NSC-70220 (SOS1-IN-1)

    SOS1 inhibitor

    SOS1-IN-1 is a SOS1 inhibitor.
    Quick View
  37. A13187
    RI-1

    RAD51 Inhibitor II

    RI-1 is a small molecule that inhibits the central recombination protein RAD51. RI-1 specifically reduces gene conversion in human cells while stimulating single strand annealing. RI-1 binds covalently to the surface of RAD51 protein at cysteine 319 that likely destabilizes an interface used by RAD51 monomers to oligomerize into filaments on DNA.
    Quick View
  38. A13245
    RO3280

    PLK1 inhibitor

    RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.
    Quick View
  39. A21546
    LDN-192960

    DYRK2 inhibitor

    LDN-192960 is an inhibitor of Haspin and Dual-specificity Tyrosine-regulated Kinase 2 (DYRK2) with IC50s of 10 nM and 48 nM, respectively.
    Quick View
  40. A21552
    CDK9-IN-1

    CDK9 inhibitor

    CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection, with an IC50 of 39 nM for CDK9/CycT1, extracted from reference, compound 87.
    Quick View
  41. A21560
    CID-1067700

    pan GTPase inhibitor

    CID-1067700 (ML282) is a pan GTPase inhibitor, and competitively inhibits Ras-related in brain 7 (Rab7) with a Ki of 13 nM.
    Quick View
  42. A21564
    (±)-BAY-1251152

    PTEF/CDK9 inhibitor

    (±)-BAY-1251152 is a racemic mixture of BAY-1251152. BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor.
    Quick View
  43. A21567
    GDC-0575 dihydrochloride

    CHK1 inhibitor

    GDC-0575 dihydrochloride (ARRY-575 dihydrochloride) is an orally bioavailable CHK1 inhibitor, with an IC50 of 1.2 nM, and has antitumor activity.
    Quick View
  44. A21570
    (-)-BAY-1251152

    PTEF/CDK9 inhibitor

    (-)-BAY-1251152 is an enanthiomer of BAY-1251152 with rotation (-). BAY-1251152 is a potent and highly selective PTEF/CDK9 inhibitor.
    Quick View
  45. A21577
    Lerociclib dihydrochloride

    CDK4/CDK6 inhibitor

    Lerociclib dihydrochloride (G1T38 dihydrochloride) is a potent and selective inhibitor of CDK4/CDK6, with IC50s of 1 nM and 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively.
    Quick View
  46. A21583
    ENMD-2076 Tartrate

    multi-targeted kinase inhibitor

    ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.
    Quick View
  47. A21613
    LDC4297

    CDK7 inhibitor

    LDC4297 is a potent and selective CDK7 inhibitor with an IC50 of 0.13 nM.
    Quick View
  48. A21628
    Fasudil

    ROCK inhibitor

    Fasudil (HA-1077; AT877), is a nonspecific ROCK inhibitor and also has inhibitory effect on protein kinases.
    Quick View
  49. A21632
    Y16

    LARG inhibitor

    Y16 is a specific inhibitor of Leukemia-associated Rho guanine nucleotide exchange factor (LARG) with a Kd value of 76 nM.
    Quick View
  50. A21648
    Rhosin hydrochloride

    RhoA subfamily Rho GTPases inhibitor

    Rhosin hydrochloride is a potent, specific RhoA subfamily Rho GTPases inhibitor.
    Quick View

Items 51-100 of 1565

Page
per page
Set Descending Direction
Shop By
Shopping Options
Category
Actions
  1. Inhibitor 1331items
  2. Agonist 1item
  3. Antagonist 3items
  4. Activator 2items
  5. Modulator 1item
  6. Degrader 3items
  7. Stabilizer 2items
  8. Ligand 2items
Target
  1. STK 1item
  2. JAK2 3items
  3. JAK3 1item
  4. CDK2 2items
  5. FLT3 2items
  6. Akt1 1item